In one case study, a prostate cancer patient with an SND1-BRAF structural rearrangement who was refractory to standard therapies showed a strong clinical response to trametinib monotherapy, an FDA-approved MEK inhibitor [38]. This evidence concerns the gene BRAF and prostate cancer.